Whereas serum irisin and nesfatin-1 levels are expected to be higher in MS patients who are heavier than the control group, the low levels of these biomarkers support the relationship between MS and irisin and nesfatin-1. This evidence concerns the gene FNDC5 and myeloid sarcoma.